{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:05:44Z","timestamp":1779771944596,"version":"3.53.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a clinically heterogeneous malignancy in which outcomes remain difficult to predict using static baseline risk models. Increasing attention has shifted toward dynamic prognostic markers, including early disease progression and early mortality; however, their relative prognostic value\u2014particularly the optimal definition of early progression\u2014and their integration with patient-related factors remain insufficiently defined in real-world populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 207 newly diagnosed MM patients treated between 2018 and 2023. Early disease progression was defined as progression within 18 (POD18) and 24 months (POD24) from treatment initiation. Early mortality was defined as death within six months of diagnosis. Overall survival (OS) and progression-free survival (PFS) were analysed using Kaplan\u2013Meier estimates and Cox regression models, including time-dependent analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median follow-up of 60 months, POD18 occurred in 44.0% and POD24 in 51.2% of patients. POD18 was strongly associated with inferior OS (HR 9.38; 95% CI 5.98\u201314.70; p &amp;lt; 0.0001) and demonstrated superior prognostic discrimination compared with POD24 (C-index 0.742 vs. 0.719). In multivariable analysis, POD18 remained the strongest independent predictor of OS, alongside comorbidity burden and performance status. Early mortality occurred in 17.9% of patients and was independently associated with advanced disease stage. Time-dependent modelling showed that the prognostic impact of baseline staging decreased over time, supporting the dynamic nature of risk in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>POD18 is a robust and clinically informative dynamic prognostic marker that outperforms POD24 in predicting survival in real-world patients with MM. Integration of early disease kinetics with baseline disease burden and comorbidity burden provides a pragmatic framework for dynamic risk stratification, particularly in settings with limited access to comprehensive molecular profiling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1812031","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:47:15Z","timestamp":1779770835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of early disease progression and early mortality in patients with multiple myeloma: a real-world cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Nada","family":"Vlaisavljevic","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Milosevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borivoj","family":"Sekulic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Nikolic","sequence":"additional","affiliation":[{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir","family":"Tomic","sequence":"additional","affiliation":[{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Savic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic of Haematology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","volume":"39","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137575","article-title":"Upfront autologous hematopoietic stem-cell transplantation improves overall survival compared with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: long-term follow-up of the randomized phase 3 EMN02\/HO95 study","volume":"136","author":"Cavo","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22861","DOI":"10.1038\/s41598-024-73822-w","article-title":"Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24","volume":"14","author":"Cao","year":"2024","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35056","article-title":"Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma","volume":"130","author":"Yan","year":"2024","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.014","article-title":"Early relapse after autologous transplant is associated with very poor survival and identifies an ultra\u2013high-risk group of patients with myeloma","volume":"20","author":"Kastritis","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1186\/s12885-025-15089-6","article-title":"The prognostic value of POD24 for multiple myeloma: a comprehensive analysis based on traditional statistics and machine learning","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients","volume":"91","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101070","article-title":"Multiple myeloma in older adults: real-world outcomes, frailty, and dynamic risk assessment","volume":"59","author":"Wildes","year":"2024","journal-title":"Blood Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18324","article-title":"Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)","volume":"198","author":"McQuilten","year":"2022","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15980","article-title":"Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a real-world study: experiences of the Polish Myeloma Group","volume":"131","author":"Charli\u0144ski","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34760","article-title":"A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma","volume":"129","author":"Grant","year":"2023","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01999-1","article-title":"An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the EBMT Chronic Malignancies Working Party","volume":"58","author":"Beksac","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:47:24Z","timestamp":1779770844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1812031"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1812031","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1812031"}}